The Biotech Analyst Group

Experienced investment group with focus on public Nordic biotech companies. We are currently focusing on companies in phase 3.

[The Biotech Analyst Group @analyst_biotech]

Disclaimer. Our content is intended for informational purpose only. Our conclusion may be wrong and may cause losses. Do your own research before making any investment.

[The Biotech Analyst Group @analyst_biotech]

@_twx17 Deal with Leaderna. Look it up together with the graph! Market Cap, MC.

[The Biotech Analyst Group @analyst_biotech]

@_twx17 Why did the sharprice drop after deal was announced? Sometime shareprice follow illogical pattern. Upfront payment likely to be revealed in nxt Q-report. MC still low. We continue to be bullish.

[Laurie Garrett @Laurie_Garrett]

7 days ago UK health officials spotted a new variant -- EG.5, dubbed "Eris". And it's already soaring as #COVID19 case rates rise. Eris is also sweeping across East Asia and has turned up in the USA.

#SARSCoV2 is still evolving: it's not "gone."

https://t.co/zUZyu5BZTb

[Ziccum @ziccum]

We are taking part in excellent discussions with leading mRNA developers at the 3rd mRNA Summit in Boston. Our Poster describing our unique drying technology for mRNA/LNP is attracting great interest and engagement https://t.co/LXt3a1HCWj #mRNA #finanstwitter

[Biovica @Biovica]

"The initial feedback has been extremely positive. HCPs have acknowledged the significant clinical utility of our intended use..."
Read the full Annual Report here: https://t.co/v5QJ5snEmS
#BiovicB #DiviTum #precisionmedicine #oncology #biomarkers #bcsm

[Biovica @Biovica]

Hot off the press! "Biovica is one of the most interesting companies in Scandinavian pharma sector." The DiviTum® TKa test is an FDA-cleared biomarker test for metastatic breast cancer monitoring.
https://t.co/cGpQd32gGV
#Biovica #DiviTum #oncology #biomarkers #bcsm

[The Biotech Analyst Group @analyst_biotech]

https://t.co/hWLHWHfcUP

[The Biotech Analyst Group @analyst_biotech]

@Kennekung Yes, we think market underestimate the potential milestones that may be reached during 2023-2024. Yesterdays interview CEO hint several milestones during startup of coming phase 2a and b. We think market may have missed that.

[The Biotech Analyst Group @analyst_biotech]

"lowering of ANGPTL4 in blood plasma was observed in the multiple ascending dose groups, with decreases of up to 24%, 90 days after the last dose, corrected for the placebo effect. This demonstrates . . . proof of mechanism . . .Lipisense engages its target as designed"

[Lipigon Pharmaceuticals @Lipigon_Pharma]

RedEye comment on yesterday’s press release. https://t.co/rxN070gsKa

[Lipigon Pharmaceuticals @Lipigon_Pharma]

RedEye comment on yesterday’s press release. https://t.co/rxN070gsKa

[Stefan K Nilsson @StefanKNilsson]

Snackar @Lipigon_Pharma med Richard på @Redeye_ https://t.co/fyKyPHImRH

[Stefan K Nilsson @StefanKNilsson]

Pharma is a marathon, not a sprint. Remember that. Work with resilience.

[The Biotech Analyst Group @analyst_biotech]

@crello https://t.co/7SfvGqsjFK

[The Biotech Analyst Group @analyst_biotech]

Lipigon Pharmaceuticals. We buy Lipigon today following the presentation today. We will post an analysis here during the week. Very undervalued company.

[The Biotech Analyst Group @analyst_biotech]

@SvenEri16996480 No idea. Don't think any leak though related to current phase III.

[The Biotech Analyst Group @analyst_biotech]

Portfolio update: Lipigon, Humana, Synact, Devysr Diagnostic, Calliditas, Vicore Pharma, Ascelia Pharma, Duearity.

[The Biotech Analyst Group @analyst_biotech]

Lipigon: Some reflexion and speculation. We think stock should be trading between 3.0-4.5 kr

[The Biotech Analyst Group @analyst_biotech]

Duearity: Received FDA 510(k) clearance on Friday, which means they are all set to go in USA. The US-market is by far their most important one. Hence, we anticipate the stock to gain strong momentum and trade at significantly higher price due to the news.

[Nature Custom Media @NatureCustom]

'Deep human biology learning' aims to discover the next big thing in oncology #AdFeature with @EisaiUS

[The Biotech Analyst Group @analyst_biotech]

Portfolio update: Humana, Synact, Devysr Diagnostic, Calliditas, Vicore Pharma, Ascelia Pharma, Duearity.